

# Guide to Writing a Letter of Appeal\*

# Composing a Letter of Appeal

When a patient's health plan denies a prior authorization (PA) request for CIMZIA® (certolizumab pegol), you can submit a letter of appeal in response to the official denial letter. In the letter of appeal, you can explain your clinical rationale for prescribing CIMZIA, provide supporting documentation that addresses the reason(s) for the denial, and request approval.

# Preparing an effective Letter of Appeal



## Follow plan-specific guidelines

Some health plans may require you to use their specific appeal form (often on its website); if there are questions, do not hesitate to directly contact the plan



## Confirm the health plan's time frame for submitting an appeal

- 🗸 If appropriate, mark the appeal request "urgent" based on the patient's needs and the health plan's timelines
  - Expedited review may be required in the case of medical urgency. When requested, you can expect to receive a decision within 72 hours. For more information on this, visit healthcare.gov.



#### Understand the reason for denial and include why you believe the decision should be reconsidered

- 🖉 If the denial was for inaccurate or incomplete information, correct or update the discrepancies
- 🖉 If the denial was for a medical reason, include specific and relevant medical information that, in your independent clinical judgment, supports the use of CIMZIA for your patient in accordance with the health plan's criteria
- 🖉 Directly address and provide supporting documents to refute any specific rationale cited in the denial

## Provide documentation as applicable

- The letter of appeal on your letterhead or health plan's appeal form (if required)
  - Patient's full name, date of birth, and health plan policy/ group number
  - Prescribing healthcare provider's name, National Provider Identifier (NPI) number, practice name, address, phone number, fax number, and email
  - Acknowledgment of the plan's policy and reasons for denial
- Rationale for why treatment is medically necessary and
- why the decision should be reconsidered
- Patient's medical history
- Summary of recommendations
- Supporting documentation, provided at the same time and in the correct order indicated in the health plan's appeal instructions - Letter of Medical Necessity - Relevant patient documentation, such as physician notes, - A copy of the plan's denial letter laboratory results, and medical records
- \*This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Use of the information in this letter does not guarantee that the health plan will provide reimbursement or coverage for CIMZIA and is not intended to be a substitute for, or an influence on, your independent medical judgment.

# Selected Important Safety Information

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Please see Important Safety Information on page 4. Please click to access the full Prescribing Information, or visit CIMZIAhcp.com





# Letter of Appeal Guide\*

# Sample Letter of Appeal

The following is a sample appeal letter that can be followed and customized based on your patient's specific medical history and identifiable information by clicking here. This sample letter can serve as a starting point for your rationale as to why this patient requires **CIMZIA®** 

(certolizumab pegol); however, medical judgment and discretion is advised when drafting this letter. Payers may also require specific forms be completed in addition to the appeal letter; therefore, knowledge of the process is critical to reversing a denial. This letter should be drafted on the physician's letterhead and be signed by the prescribing physician.

Date	mm/dd/yyyy		Date of Denial Letter		dd/yyyy			
Contact Name, Title	Contact Name. Title		Denied Claim Number		al Reference Number			
Health Insurance Plan or PBM	Health Insurance Plan or PB	BM	Patient Name	Patie	nt Name			
Plan Address	Plan Address		Patient Date of Birth	mm/	dd/yyyy			
Plan City, State, ZIP Code	Plan City, State, Zip Code		Insurer	Insur	er			
Policy Override Request 🛛 🖝 for Co	verage Denial of CIMZIA (o	ertolizumab pegol)	Policy Number	Polic	y Number			
Request for Expedited Review Due to N	Aedical Urgency		Group Number	Grou	up Number			
To Whom It May Concern,								
I am writing on behalf of my pat	ient Patient Full Name	lo r	appeal the coverage denial for treat	ment with CIMZ	A® (certolizumab			
pogol) for Moderate-to-severe Crot		-	appear and contendity contained incom					
The aforementioned letter of der as the reason for coverage deni	nial stated List Reasons Fo	or Denial						
This appeal letter provides inform	nation regarding my po	atient's medical his	story as well as treatment rationale fo	or the use of CIN	ZIA.			
Patient Medical Overview								
Patient Name is a[n] ##	-year-old Sex borr	n mm/dd/yyyy wh	to was diagnosed with ICD-10 CM Ca	ode Diagnostic co	de description			
os of mm/dd/yyyy . Patient Name	's a	urrent and past me	edical history support the use of CIM	ZIA to manage t	heir			
Moderate-to-severe Crohn's Disease	•	-						
🗌 ladicata hara, hu addina a c	hack mark that the pat	iont door not have	e active tuberculosis or other serious	infactions knowin	ad by come bealth			
plans). If the patient has any				inections frequi	ed by some nealin			
Infection Name and			Treatment Type(s), Treatment Start	/Stop Date(s), a	ind Reason for			
Infection Name and Affected Part(s) of the Body	Infection Name and Affecte Body	ed Part(s) of the	Treatment Type(s), Treatment Start Therapy Discontinuation	/Stop Date(s), c	ind Reason for			
		ad Pant(s) of the	Therapy Discontinuation Treasment Type(s), Treasment Start/Stop					
Alfected Part(s) of the Body Anticipated			Therapy Discontinuation					
Affected Part(s) of the Body	Body		Therapy Discontinuation Treasment Type(s), Treasment Start/Stop					
Alfected Part(s) of the Body Anticipated	Body Anticipated Resolution Date	5	Therapy Discontinuation Treasment Type(s), Treasment Start/Stop			,		
Alfected Part(s) of the Body Anlicipated Resolution Date Medical History (including sig Provide relevant clinical stars and symp	Boxty Anticipated Resolution Date	poratory results)	Theoropy Discontinuation Treasment Type(s), Treasment Start/Stop Discontinuation	Date(s), and Reason	for Thorapy	1	/	
Alfected Part(s) of the Body Anlicipated Resolution Date Medical History (including sig Provide relevant clinical stars and symp	Boxty Anticipated Resolution Date Ins, symptoms, and lob stores and describe the sever inevant patient-specific clinics	boratory results) by of disease of your p	Iheropy Discontinuction Treament Type(s), Treament Start/Stop Discontinuation Discontinuation	Date(s), and Reason	for Thorapy		/	
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant cirical growmations of Related specific clinical preventations of	Boxty Anticipated Resolution Date Ins, symptoms, and lob stores and describe the sever inevant patient-specific clinics	boratory results) by of disease of your p	Iheropy Discontinuction Treament Type(s), Treament Start/Stop Discontinuation Discontinuation	Date(s), and Reason	for Thorapy			
Alfected Part(s) of the Body Anlicipated Resolution Date <b>Medical History (including sig</b> Provide relevant chinical signs and symp Irakate spacefile clinical presentations, n itme since initial diagnoses, past treatme	Budy Anticipated Resolution Data ns, symptoms, and lob norms and describe the sever nerware parisms-specific clinic, ans used, and pasters-reporte	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuation Treamer, Type(s), Treament Start/Stop Discontinuation patient's current presentation and any disease anting serious medical need, and previous mea to past reaments.	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:		/	
Alfected Part(s) of the Body Anlicipated Resolution Date <b>Medical History (including sig</b> Provide relevant chinical signs and symp Irakate spacefile clinical presentations, n itme since initial diagnoses, past treatme	Budy Anticipated Resolution Data ns, symptoms, and lob norms and describe the sever nerware parisms-specific clinic, ans used, and pasters-reporte	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuction Treament Type(s), Treament Start/Stop Discontinuation Discontinuation	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:		/	
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant citical agreementations, intende specific citical preventations, intendence initial diagnoses, part rearms Provide clinical notes associated with p	Budy Anticipated Resolution Data ns, symptoms, and lob norms and describe the sever nerware parisms-specific clinic, ans used, and pasters-reporte	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuation Treamer, Type(s), Treament Start/Stop Discontinuation patient's current presentation and any disease anting serious medical need, and previous mea to past reaments.	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:	]	/	
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant citical growned and inclusio specific citical preventions there since initial diagnoses, past reasons Provide clinical notes associated with p testing results.	Body Anticipatod Rosolution Data Ins, symptoms, and lob across and describe the sover intervent patient-specific clinic ans used, and patient-reporte est visits that support informat	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuation Treamer, Type(s), Treament Start/Stop Discontinuation patient's current presentation and any disease anting serious medical need, and previous mea to past reaments.	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:	]	/	
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide retevant clinical gravenatory, n induste specific clinical gravenatory, n may ance whild diagnose, part rearry Provide clinical notes associated with p testing results. Treatment Rationale	Body Anticipatod Resolution Date ins, symptoms, and lob across and describe the source and describe the sourceffe clinic ans used, and patient reporte est visits that support informat provided.	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuation Treamer, Type(s), Treament Start/Stop Discontinuation patient's current presentation and any disease anting serious medical need, and previous mea to past reaments.	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:	]	/	
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide retevant clinical gravenatory, n inclusion specific clinical gravenatory, n into ance while diagnose, part rearres provide clinical notes associated with p testing results. Treatment Rationale Regarding the reason for denial	Body Anticipatod Resolution Date ins, symptoms, and lob across and describe the source and describe the sourceffe clinic ans used, and patient reporte est visits that support informat provided.	b borationy results) ity of disease of your p al scenarios demonstra d experience reliated t	Iheropy Discontinuation Treamer, Type(s), Treament Start/Stop Discontinuation patient's current presentation and any disease anting serious medical need, and previous mea to past reaments.	Date(s), and Reason progression based o merris. Examples ma	for Thorapy on your modical opinion. y include the following:	]		
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant clinical growing and related spacefic entirely prevariant related spacefic entirely prevariant Provide clinical notes associated with p testing results. Treatment Rationale Relations the reason for deniral Reterans Research for Denist and Ration In my professional opinion, CIM	Rody Anticipated Resolution Date ans, symptoms, and lat anome and describes the sever however patient-specific citric, and used, and patient-reports ast visits that support informat provided. ale For Insumere IZIA is the most approp	poratory results) by of disease of your is a consister demonstration of experience related to fion noted in this section riote treatment for	Heropy Discontinuction     Treasment Type(q), Treasment Start/Stop     Discontruistion     Discontruistion     antion***********************************	Date(s), and Reason progression based mere: Examples ma nere relevant), and a	tor Therapy on your medical opinion. y incluste the following: ny relevant laboratory	]		
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide retware clinical growmatare, n time since while diagnose, par rearries measure while diagnose, par rearries provide clinical notes associated with p testing results. Treatment Rationale Regarding the reason for denial Returnas Reason for Denial and Ration In my professional opinion, CIM based on their medical history, o	Body Anticipatod Resolution Data Ins, symptoms, and lak across and describe the source for used, and patient-reporte ast visits that support informat provided: asie For Treament IZIA is the most approp current symptoms and c	poratory results) by of dimension of your at screamics demonstration d experience related is sion noted in this section into the treatment for ondition sevently, i	Iheropy Discontinuation     Treasment Type(q), Treasment Start/Stop     Discontinuation     patient's current presentation and any disease     antig serious medical need, and previous treas     an, acoring forms, photos of effected areas (wi     Patient Name 's Moderate     and the current data surrounding the	Date(s), and Reason progression based mere: Examples ma nere relevant), and a	tor Therapy on your medical opinion. y incluste the following: ny relevant laboratory			
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant clinical growing and related spacefic entirely prevariant related spacefic entirely prevariant Provide clinical notes associated with p testing results. Treatment Rationale Relations the reason for deniral Reterans Research for Denist and Ration In my professional opinion, CIM	Body Anticipatod Resolution Data Ins, symptoms, and lak across and describe the source for used, and patient-reporte ast visits that support informat provided: asie For Treament IZIA is the most approp current symptoms and c	poratory results) by of dimension of your at screamics demonstration d experience related is sion noted in this section into the treatment for ondition sevently, i	Iheropy Discontinuation     Treasment Type(q), Treasment Start/Stop     Discontinuation     patient's current presentation and any disease     antig serious medical need, and previous treas     an, acoring forms, photos of effected areas (wi     Patient Name 's Moderate     and the current data surrounding the	Date(s), and Reason progression based mere: Examples ma nere relevant), and a	tor Therapy on your medical opinion. y incluste the following: ny relevant laboratory			
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide retware clinical growmatare, n time since while diagnose, par rearries measure while diagnose, par rearries provide clinical notes associated with p testing results. Treatment Rationale Regarding the reason for denial Returnas Reason for Denial and Ration In my professional opinion, CIM based on their medical history, o	Buxty Anticipated Resolution Date ans, symptoms, and lot atoms and describe the average atoms and describe the source intervent patient-reporte and used, and patient-reporte ast visits that support informat provided: also For Treatments IZIA is the most approp current symptoms and c 1 vill also be enclosing	porationry results) ty of disease of your p a scenarios demonstrat d experience related t icon noted in this section riote treatment for ondition sevenity, Las Enclosed Inform	Iheropy Discontinuation     Insumer: Type(s), Treament Start/Stop     Decontinuation     patient's current presentation and any disease     antiger services medical need, and previous treat     reations forms, photos of affected areas (w     Patient Name 's Moderate     and the current data surrounding the     sation	Date(s), and Reason progression based mere: Examples ma nere relevant), and a	for Thorapy on your medical opinion. y include the following: ny relevant laboratory Disease Disease Cy of CIMZIA.			
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant clinical preventations, n interacter specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, Provide clinical notes associated with p testing media. Treatment Rationale Responding the reason for denial Reterant Reason for Dentel and Ratios In my professional opinion, CIM based on their medical history, o To further support my reasoning, Based on the above, I believe th	Budy Anticipated Resolution Date ms, symptoms, and lab anticipated describe the sover investme patient-specific citric ans used, and patient-reporte ast visits that support informat provided: tals for Treatment IZIA is the most approp current symptoms and c 1 will also be enclosing the coverage determinal	booratory results) by of disease of your p it examines demonstration desperience reliated t desperience reliated t desperience reliated t dison noted in this section rilate treatment for ondition sevenity, i l Lat Enclosed Inform tion for Patient Name	Iheropy Discontinuation     Insumer: Type(s), Treament Start/Stop     Decontinuation     patient's current presentation and any disease     antiger services medical need, and previous treat     reations forms, photos of affected areas (w     Patient Name 's Moderate     and the current data surrounding the     sation	Dato(s), and Reason progression based o mems: Examples ma nere relevant), and a sto-severe Crothi's I safety and effice should be reverse	for Thorapy on your medical opinion. y include the following: ny relevant laboratory Disease Disease Cy of CIMZIA.			
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant clinical preventations, n interacter specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, interaction specific initical preventations, Provide clinical notes associated with p testing media. Treatment Rationale Responding the reason for denial Reterant Reason for Dentel and Ratios In my professional opinion, CIM based on their medical history, o To further support my reasoning, Based on the above, I believe th	Body Anticipated Resolution Date <b>ns, symptoms, and lot</b> anoms and describes the sover involvem patient-reporte and values the support informat provided: nin For Insument IZIA is the most approp purrent symptoms and c 1 will also be enclosing the coverage determinant of them. If any addition	poratory results) by of disease of your a laremarks demonstrated a experience related t icon noted in this section riate treatment for ondition sevenity, q lat Enclosed Inform licon for Patient Name and questions arise	Iheropy Discontinuction     Treatment Type(q), Treatment Start/Step I     Decontruition     Treatment Type(q), Treatment Start/Step I     Decontruition     patient's current presentation and any disease     to past treatments.     an, scoring forms, photos of affected areas (w  r Patient Name     's Moderate and the current data surrounding the station     's CIMZIA +	Dato(s), and Reason progression based o mems: Examples ma nere relevant), and a sto-severe Crothi's I safety and effice should be reverse	for Thorapy on your medical opinion. y include the following: ny relevant laboratory Disease Disease Cy of CIMZIA.	]		
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provide relevant citrical grownary on relevate specific entirical preventations, interesting including and grows, part treatment restrict specific entirical preventations, interesting including Provide clinical notes associated with p testing including Provide clinical notes associated with p testing including reaction and Research for deniral Reteretaing the reason for deniral Reteretain Research for Denital and Ration In my professional opinion, CIM based on their medical history, of To further support my reasoning. Based on the above, I believe it medically necessary medication	Body Anticipated Resolution Date <b>ns, symptoms, and lot</b> anoms and describes the sover involvem patient-reporte and values the support informat provided: nin For Insument IZIA is the most approp purrent symptoms and c 1 will also be enclosing the coverage determinant of them. If any addition	by of disease of your p ts creations of your p ts creations of the section icon noted in this section riate treatment for ondition sevently, l Lat Enclosed Inform from for Patient Name and questions aris his request.	Iheropy Discontinuction     Treatment Type(q), Treatment Start/Step I     Decontruition     Treatment Type(q), Treatment Start/Step I     Decontruition     patient's current presentation and any disease     to past treatments.     an, scoring forms, photos of affected areas (w  r Patient Name     's Moderate and the current data surrounding the station     's CIMZIA +	Dato(s), and Reason progression based o mems: Examples ma nere relevant), and a sto-severe Crothi's I safety and effice should be reverse	tor Therapy an your medical opinion. y include the following: ny relevant laboratory Decease scy of CIMZIA. ed, as it is a			
Alfected Part(s) of the Body Anticipated Resolution Date Medical History (including sig Provident elevant clinical preventations, n interaction specific clinical preventations, n interaction specific clinical preventations, interaction specific clinical preventations, mention of the state of the state of the resting results. Treatment Rationale Responding the reason for denial Reterain Reason for Denial and Ration In my professional opinion, CIM based on their medical history, o To further support my reasoning. Based on the above, I believe the medically necessary medication Thank you in advance for your in	Budy Anticipated Resolution Date ms, symptoms, and lot atoms and describe the service and describe the service and describe the service and service the service and patient reports and patient reports and patient reports provided: as For Treament IZIA is the most approp current symptoms and c I will also be enclosing as coverage determinal for them. If any addition mmediate attention to the Physician's Name, Cred	by of disease of your p ts creations of your p ts creations of the section icon noted in this section riate treatment for ondition sevenity, i Lat Enclosed Inform icon for Patient Name nal questions aris his request.	Iheropy Discontinuation     Treatment Type(q), Treatment Start/Stop     Decontinuation     patient's current presentation and any disease     antiger secure presentation and any disease     antiger secure presentation and any disease     antiger secure presentation and any disease     and previous medical need, and previous treat     and the current data surrounding the     sation     s CIMZIA :     e, please feel free to contract me to contract the toperation.	Dato(s), and Reason progression based o mems: Examples ma nere relevant), and a eto-severe Crothis I safety and effice should be reverse liscuss.	tor Therapy on your medical opinion. y include the following: ny relevant laboratory Decaaso scy of CIMZIA. ed, as it is a Number			

ick to access the full scribing Information

Directly address the reason for denial nd include relevant edical information hat, in your clinical udgment, supports your patient's appropriate use in ccordance with the alth plan's criteria. See next page for pecific examples of tient medical history consider including.

\*This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Use of the information in this letter does not guarantee that the health plan will provide reimbursement or coverage for CIMZIA and is not intended to be a substitute for, or an influence on, your independent medical judgment.

Please see Important Safety Information on page 4. Please click to access the full Prescribing Information, or visit CIMZIAhcp.com





# Details to consider including with your CIMZIA® (certolizumab pegol) Letter of Appeal\*



# **Examples of medical history for a Letter of Appeal**

# Documented diagnosis of CIMZIA indication, including:

- 🕑 Reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
- 🕑 Treatment of adults with moderately or severely active rheumatoid arthritis.
- Treatment of adult patients with active psoriatic arthritis.
- Treatment of adults with active ankylosing spondylitis.
- 🖉 Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
- $\bigotimes$  Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

# 🗸 Pertinent signs and symptoms, laboratory test results, and clinical classifications responsible for the patient's diagnosis.

🕑 Include information on any complications due to diagnosed disease.

All treatments the patient has trialed, duration of the trial, dosing, and any impact (positive or negative) these treatments had on the patient and their condition, and the reason for discontinuation.

# Reasons the patient cannot/should not use any of the other treatment options listed in the utilization management criteria.

- 🕑 Consider drug-drug interactions, drug-condition interactions, and significant patient medical history that may steer your decisions.
- Patient populations (e.g., pregnancy status)

Note: This is not an all-inclusive list. Please use clinical judgment when deciding materials to include for review.



# Common reasons for denial

Below is a list of some of the most common reasons a health plan my initially deny coverage of CIMZIA that can be addressed in a Letter of Appeal using the patient's medical history and your clinical judgment.

# Unclear understanding of CIMZIA indication

Lack of information regarding previous treatments, including those required for CIMZIA initiation

Missing clinical information to support initiation of CIMZIA, including medical history, all pertinent laboratory results, and all previously trialed therapies, including reason for their discontinuation

\*This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Use of the information in this letter does not guarantee that the health plan will provide reimbursement or coverage for CIMZIA and is not intended to be a substitute for, or an influence on, your independent medical judgment.

Please see Important Safety Information on page 4. Please click to access the full Prescribing Information, or visit CIMZIAhcp.com



#### **INDICATIONS**

CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

#### **IMPORTANT SAFETY INFORMATION**

#### **CONTRAINDICATIONS**

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

#### **SERIOUS INFECTIONS**

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

**Reported infections include:** 

- Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

- Do not start CIMZIA during an active infection, including localized infections.
- Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
- If an infection develops, monitor carefully and initiate appropriate therapy.

#### MALIGNANCY

#### Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

- Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
- In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.

#### Please click to access the full **<u>Prescribing Information</u>**, or visit <u>CIMZIAhcp.com</u>



CIMZIA® is a registered trademark of the UCB Group of Companies. ©2023 UCB, Inc. All rights reserved. US-P-CZ-AS-2300097

- In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
- Malignancies, some fatal, have been reported among children, adolescents, and young
  adults being treated with TNF blockers. Approximately half of the cases were lymphoma,
  while the rest were other types of malignancies, including rare types associated with
  immunosuppression and malignancies not usually seen in this patient population.
- Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
- Cases of acute and chronic leukemia were reported with TNF blocker use.

#### **HEART FAILURE**

 Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

#### **HYPERSENSITIVITY**

 Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex.

#### **HEPATITIS B VIRUS REACTIVATION**

- Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
- Test patients for HBV infection before initiating treatment with CIMZIA.
- Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
- Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

#### **NEUROLOGIC REACTIONS**

 TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

#### **HEMATOLOGIC REACTIONS**

- Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
- Consider stopping CIMZIA if significant hematologic abnormalities occur.

#### DRUG INTERACTIONS

 $\bullet$  Do not use CIMZIA in combination with other biological DMARDS.

#### AUTOIMMUNITY

• Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

#### IMMUNIZATIONS

• Patients on CIMZIA should not receive live or live-attenuated vaccines.

#### **ADVERSE REACTIONS**

• The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).



Date		Date of Denial Letter
Contact Name, Title		
Health Insurance Plan	or PBM	Patient Name
Plan Address		Patient Date of Birth
Plan City, State, ZIP Co	ode	Insurer
	for Coverage Denial of CIMZIA (certolizumab pegol)	Policy Number
		Group Number

#### To Whom It May Concern,

I am writing on behalf of my patient, , to appeal the coverage denial for treatment with CIMZIA® (certolizumab pegol) for The aforementioned letter of denial stated

as the reason for coverage denial.

This appeal letter provides information regarding my patient's medical history as well as treatment rationale for the use of CIMZIA.

#### Patient Medical Overview

	is a[n]	-year-old	born	who was diagnosed with
as of			's current o	and past medical history support the use of CIMZIA to manage their

Indicate here, by adding a check mark, that the patient does not have active tuberculosis or other serious infections (required by some health plans). If the patient has any serious infections, please list them below:

Infection Name and Affected Part(s) of the Body Treatment Type(s), Treatment Start/Stop Date(s), and Reason for Therapy Discontinuation

Anticipated Resolution Date

#### Medical History (including signs, symptoms, and laboratory results)

#### **Treatment Rationale**

Regarding the reason for denial provided:

In my professional opinion, CIMZIA is the most appropriate treatment for 's based on their medical history, current symptoms and condition severity, and the current data surrounding the safety and efficacy of CIMZIA. To further support my reasoning, I will also be enclosing

Based on the above, I believe the coverage determination for 's CIMZIA should be reversed, as it is a medically necessary medication for them. If any additional questions arise, please feel free to contact me to discuss. Thank you in advance for your immediate attention to this request.

Physician's Name, Credentials	Physician's Phone Number
Physician's Identification Number	Physician's Fax Number
Physician's Practice Name	Physician's Email